Skip to content

Epilepsy management in elderly

Comparing efficacy and tolerability of lamotrigine and levetiracetam in elderly patient with diagnosed epilespy

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013021211560N3
Enrollment
95
Registered
2013-05-18
Start date
2012-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly epilepsy. Epilepsy

Interventions

Intervention 1: Lamotrigine was start in 25mg/day and continue to 200mg/day. Intervention 2: Levetiracetam was start in 250mg/day and continue to 1000mg/day.
Treatment - Drugs
Lamotrigine was start in 25mg/day and continue to 200mg/day
Levetiracetam was start in 250mg/day and continue to 1000mg/day

Sponsors

Deputy of Research,Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : age>60 years old; one year diagnosis; two or more attack in the last year; one and more attack in 6 months ago; life expectancy more one year; unprovoked or generalized epilepsy; no history of lamotrigine and levetiracetam sensitivity and no history of mental disorder. Exclusion criteria: no tolerability to drug reaction; severe complication; lost to follow up; drug and alcohol abuse; low level of consciousness after drug use due to underlying disease and death.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Epilepsy management. Timepoint: Four weeks after drug use. Method of measurement: Interview.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPardis Etemadi

Sina Hospital, Tehran University of Medical Sciences

pardisedemadi@tums.ac.ir+98 21 6312 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026